Skip to main content
Premium Trial:

Request an Annual Quote

Two RNAi-Related Patent Applications Published by the US Patent Office: Jul 9, 2004


Title: Compositions and Methods for Treating Trail-Resistant Cancer Cells. Number: 20040126791. Filed: Sept. 19, 2003. Lead Inventor: Harald Wajant, Ribopharma (Alnylam).

The invention, the patent application’s abstract states, “relates to a double-stranded ribonucleic acid for inhibiting the expression of a cellular FLICE-like inhibitory protein gene, comprising a complementary RNA strand [that] is substantially identical to at least a part of a cFLIP gene.”

The abstract adds that the invention also relates “to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for inhibiting the expression of a cFLIP gene in a cell, methods for improving the effectiveness of an apoptosis-inducing drug, and methods for treating cancer using the pharmaceutical composition.”

Title: Colon Carcinoma-Related Oligonucleotides and Methods of Use. Number: 20040127450. Filed: Jan. 12, 2004. Inventor: Ramaswamy Narayanan, Florida Atlantic University.

According to the patent application’s abstract, the invention relates to “synthetic oligonucleotides (antisense, ribozymes, siRNA, and triple helix molecules) useful in down-regulating expression of a colon carcinoma-related gene nucleic acid or protein in a cell; and treatment method using said oligonucleotides alone or in combination with chemotherapy or radiation therapy.”

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.